Physician profile
John Q Binhlam
NPI 1467596080
$19,282.18
in general payments reported to CMS, 2019-2025
40 companies · $2,005 in 2025
The $2,005 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,455 · 2020: $4,073 · 2021: $2,162 · 2022: $2,961 · 2023: $2,587 · 2024: $2,039 · 2025: $2,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,482 · Education: $118 · Travel and Lodging: $31.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,481.77 |
| Education | $118.43 |
| Travel and Lodging | $31.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,915.26 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $2,888.84 | 2019-2025 | |
| Abbvie INC. | $1,995.24 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,255.49 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,220.11 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,085.23 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $722.37 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $669.15 | 2019-2025 | |
| Genzyme Corporation | $566.14 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $563.48 | 2019-2025 | Tremfya |
| Biofrontera INC. | $561.91 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Leo Pharma INC. | $492.46 | 2021-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $401.55 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $391.62 | 2022-2024 | Sotyktu |
| Amgen INC. | $354.47 | 2020-2025 | Otezla, Otezla |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Binhlam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.